Quick Answer
Immix Biopharma, Inc. reported R&D Expense of $16.26 million for fiscal year 2025.
Immix Biopharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $16.26M | +44.0% |
| 2024 | $11.29M | +29.3% |
| 2023 | $8.74M | +108.2% |
| 2022 | $4.20M | +3216.1% |
| 2021 | $126.5K | -49.0% |
| 2020 | $248.1K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.58M | +3.1% | +15.4% |
| June 30, 2025 | $3.97M | +78.6% | +101.1% |
| March 31, 2025 | $1.98M | -39.2% | -55.6% |
| September 30, 2024 | $4.45M | +111.1% | +99.9% |
| June 30, 2024 | $2.22M | +0.7% | -31.5% |
| March 31, 2024 | $3.25M | +146.3% | +54.3% |
| September 30, 2023 | $2.11M | +202.6% | -4.7% |
| June 30, 2023 | $2.21M | +263.5% | +67.5% |
- Immix Biopharma, Inc. showed an increase of +44.0% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Immix Biopharma, Inc.’s r&d expense has grown by 6451.9% (from $248.1 thousand to $16.26 million).
- The most recent figure is from Immix Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: